Glycosphingolipid Dysregulation in Congenital Disorders of Glycysolation (CDG

Organisation/Company KU LEUVEN Department Biomedical sciences Research Field Medical sciences » Medicine Researcher Profile First Stage Researcher (R1) Final date to receive applications 10 Aug 2026 - 23:59 (UTC) Country Belgium Type of Contract Temporary Job Status Full-time Offer Starting Date 1 Oct 2026 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Reference Number BAP
- Is the Job related to staff position within a Research Infrastructure? No

Congenital disorders of glycosylation (CDG) comprise more than 200 individually rare inherited metabolic disorders and represent one of the most rapidly expanding groups of inborn errors of metabolism. While abnormalities of protein glycosylation have traditionally been considered the primary disease mechanism, many CDG patients present with severe neurological manifestations that remain only partially understood.

Recent work from our research group has identified glycosphingolipids (GSLs), including gangliosides, as a potentially critical but under-explored disease mechanism in CDG. Because glycosphingolipids constitute the majority of glycan structures in the central nervous system and are essential for neuronal development, signalling and synaptic function, understanding their dysregulation may open entirely new therapeutic avenues.
This PhD project forms part of a larger translational research programme aimed at developing mechanism-based treatments for CDG. The successful candidate will work at the intersection of rare disease research, neuroscience, systems biology, metabolomics and lipidomics.
The project builds upon unique patient cohorts, extensive preliminary data, and internationally recognised expertise in congenital disorders of glycosylation.
We are looking for a highly motivated candidate who:

• Holds (or will soon obtain) a Master's degree in Biomedical Sciences, Biology, Medicine, Bioengineering, Biochemistry, Biotechnology, Pharmaceutical Sciences, Bioinformatics or a related discipline
• Has obtained excellent academic results
• Demonstrates a strong interest in rare diseases, metabolism, neuroscience or molecular medicine
• Has an interest in advanced laboratory techniques and data analysis
• Possesses strong communication and scientific writing skills
• Is able to work independently while thriving in a collaborative multidisciplinary team
• Is fluent in English
• Experience with cell culture, molecular biology, mass spectrometry, bioinformatics, programming or omics technologies is considered an asset but is not mandatory.

• Objective 1 - Defining glycosphingolipid abnormalities in CDGThe candidate will perform comprehensive glycosphingolipid and ganglioside profiling in an extensive collection of patient-derived fibroblasts representing multiple CDG subtypes. Using state-of-the-art lipidomics and tracer-based metabolomics, metabolic bottlenecks and pathway rerouting events will be identified. Treatment options will be explored.
• Objective 2 - Investigating disease mechanisms and therapeutic opportunities
  
  Key findings will be validated in neuronal-relevant cellular models generated through CRISPR-mediated genetic engineering and pharmacological perturbation approaches. Multi-omics integration (lipidomics, metabolomics, proteomics and transcriptomics) will be used to identify pathogenic mechanisms and nominate therapeutic interventions, including glycosphingolipid supplementation and drug repurposing strategies.

• Conduct innovative research leading to a PhD degree
• Perform experiments involving cell culture, lipidomics, metabolomics and molecular biology
• Analyse and integrate complex multi-omics datasets
• Present research findings at national and international meetings
• Publish research in high-quality scientific journals
• Participate in national and international collaborations
• Support supervision of Master's thesis students

KU Leuven offers a stimulating international research environment with excellent training opportunities. The successful candidate will join a dynamic team of clinicians, PhD students, postdoctoral researchers and technicians working on rare metabolic diseases and translational therapeutic development.

Successful completion of the programme will lead to the degree of Doctor of Biomedical Sciences.
FUNDING AND APPOINTMENT
- Fully funded PhD position (4-year trajectory subject to successful evaluation according to KU Leuven regulations)- Competitive salary according to KU Leuven doctoral scholarship scales
- Expected start date: flexible, preferably October 2026

- Location:

Leuven, Belgium
For more information please contact Prof. dr. Peter Witters, mail:  or Prof. dr. Bart Ghesquière, mail:  .